TrialThe Lancet. Oncology2022

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.

Matthew R Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.